X4 Pharmaceuticals (NASDAQ:XFOR) Price Target Cut to $1.50 by Analysts at HC Wainwright

X4 Pharmaceuticals (NASDAQ:XFOR) had its price objective reduced by research analysts at HC Wainwright from $5.00 to $1.50 in a research report issued on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price objective would indicate a potential upside of 271.75% from the company’s previous close.

Separately, Stifel Nicolaus decreased their price target on shares of X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating for the company in a research report on Thursday.

X4 Pharmaceuticals Stock Performance

NASDAQ XFOR opened at $0.40 on Thursday. The company has a debt-to-equity ratio of 0.79, a current ratio of 6.07 and a quick ratio of 6.04. The company has a market cap of $67.99 million, a P/E ratio of -4.42 and a beta of 0.39. The stock has a 50-day moving average of $0.59 and a two-hundred day moving average of $0.75. X4 Pharmaceuticals has a 1-year low of $0.26 and a 1-year high of $1.60.

X4 Pharmaceuticals (NASDAQ:XFOR) last posted its quarterly earnings data on Wednesday, August 14th. The company reported $0.01 EPS for the quarter. The business had revenue of $3.43 million during the quarter. As a group, analysts anticipate that X4 Pharmaceuticals will post -0.65 EPS for the current year.

Insider Activity at X4 Pharmaceuticals

In related news, CFO Adam S. Mostafa sold 230,645 shares of the business’s stock in a transaction on Monday, October 7th. The shares were sold at an average price of $0.55, for a total transaction of $126,854.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Paula Ragan sold 239,436 shares of the firm’s stock in a transaction on Monday, October 7th. The shares were sold at an average price of $0.55, for a total value of $131,689.80. Following the completion of the sale, the chief executive officer now owns 1,057,713 shares in the company, valued at approximately $581,742.15. This represents a 18.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 580,800 shares of company stock valued at $321,447 over the last 90 days. 1.62% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On X4 Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD lifted its position in shares of X4 Pharmaceuticals by 46.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 39,307 shares of the company’s stock worth $55,000 after buying an additional 12,514 shares during the last quarter. Rhumbline Advisers grew its position in shares of X4 Pharmaceuticals by 14.6% in the 2nd quarter. Rhumbline Advisers now owns 187,246 shares of the company’s stock valued at $109,000 after buying an additional 23,831 shares during the last quarter. Verition Fund Management LLC acquired a new stake in X4 Pharmaceuticals during the 3rd quarter worth $30,000. XTX Topco Ltd lifted its position in X4 Pharmaceuticals by 41.7% in the third quarter. XTX Topco Ltd now owns 157,642 shares of the company’s stock valued at $106,000 after acquiring an additional 46,397 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new position in X4 Pharmaceuticals in the third quarter valued at $37,000. Hedge funds and other institutional investors own 72.03% of the company’s stock.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.